✦ LIBER ✦

Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression

✍ Scribed by Ando, Masashi; Yamauchi, Hideko; Aogi, Kenjiro; Shimizu, Satoru; Iwata, Hiroji; Masuda, Norikazu; Yamamoto, Naohito; Inoue, Kenichi; Ohono, Shinji; Kuroi, Katsumasa; Hamano, Tetsutaro; Sukigara, Tamie; Fujiwara, Yasuhiro

Book ID: 125356809
Publisher: Springer US
Year: 2014
Tongue: English
Weight: 296 KB
Volume: 145
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-014-2947-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of metronomic paclitaxe

A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer

✍ Masuda, N.; Higaki, K.; Takano, T.; Matsunami, N.; Morimoto, T.; Ohtani, S.; Miz 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 519 KB

A multicenter randomized phase II study

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

✍ Jean-Yves Pierga; Suzette Delaloge; Marc Espié; Etienne Brain; Brigitte Sigal-Za 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 236 KB

Randomized phase II study of amifostine

Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II–IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: A follow-up study after RTOG 98-01

✍ Maria Werner-Wasik; Corey Langer; Benjamin Movsas 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 95 KB